New diabetes clinical trial: Phase 2, Randomized, Open-Label, Crossover, PD/PK Study of a Novel Pram-Insulin Co-Formulation in Adults With T1D

Published on: August 30, 2019 at 07:00PM
Conditions:   Diabetes Mellitus, Type 1;   Insulin-dependent Diabetes Mellitus
Interventions:   Drug: PRAM9;   Drug: Regular Insulin + Pramlintide;   Drug: Regular Insulin
Sponsor:   Xeris Pharmaceuticals
Recruiting